Alemtuzumab (Lemtrada®)

Alemtuzumab (Lemtrada) is covered only for FDA‑approved relapsing forms of MS in patients ≥17 years (non‑relapsing indications and patients <17 are excluded) and must be prescribed by or in consultation with a neurologist/MS specialist. Initial approval requires prior use of Kesimpta, Ocrevus, or Tysabri OR inadequate efficacy/intolerance to two MS DMTs OR documentation of highly‑active/aggressive disease per clinical/MRI criteria; reauthorization requires ≥12 months since the last Lemtrada course plus documented clinical benefit or stabilization, approvals are time‑limited (initial 5 days; reauthorization 3 days), and dosing is 12 mg IV ×5 days initially and 12 mg IV ×3 days for additional courses ≥12 months apart.

"Lemtrada is indicated for the treatment of relapsing forms of multiple sclerosis (MS)."

Sign up to see full coverage criteria, indications, and limitations.